Australian Broker Call

Morgans rates AGL as Hold (3) -

The broker has increased its AGL Energy target to $18.33 from $17.85 to account for higher electricity prices. Despite higher prices, the broker sees a challenging FY20 for the company given the Loy Yang outage and regulation of default electricity offers. Hold retained.

Target price is $18.33 Current Price is $20.22 Difference: minus $1.89 (current price is over target).
If AGL meets the Morgans target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $19.21, suggesting downside of -5.0% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates ALL as Buy (1) -

Citi stopped covering in 2018 and at the time had labeled Aristocrat Leisure a "Conviction Buy". The broker has returned with a Buy rating and $35 price target. Growth for the medium term outlook should be secured via the land based operations, argue the analysts, while acknowledging the move into Digital adds a degree of uncertainty in the short term.

"High quality, above market growth" that's how Citi describes the investment opportunity offered by Aristocrat Leisure. Underlying lays high single-digit organic growth, supported by the fact a large chunk of the revenues are now recurring.

In Digital, Citi estimates the company's market share is circa 2% of a US$69bn mobile market that is growing at an estimated 13% per annum over the next three years. On the broker's calculations, the Digital operations are presently discounted by investors, which offers a sufficient margin of safety, in its view. Interesting detail: the last price target in our admin was $36 last year.

Target price is $35.00 Current Price is $29.12 Difference: $5.88
If ALL meets the Citi target it will return approximately 20% (excluding dividends, fees and charges).

Current consensus price target is $32.19, suggesting upside of 10.5% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.9

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates AMP as Sell (5) -

Citi had downgraded to Sell/High Risk from Neutral in May, with a price target of $1.90 and both key elements remain unchanged after yet another update on AMP. Forecasts have been slightly amended for marking-to-market, but overall the analysts believe the market is no longer interested in short term earnings and changes in earnings.

Citi analysts now believe all that matters is what strategy will be announced to reshape the once mighty AMP. Citi thinks a substantial cost-out program is under way. The analysts remain sceptical whether such a move will be sufficient to offset declining revenues.

Whatever management and the board come up with, Citi retains the view that any successful turnaround can only occur via a long and arduous road to reinvent the company. Hence the Sell rating.

Target price is $1.90 Current Price is $1.81 Difference: $0.09
If AMP meets the Citi target it will return approximately 5% (excluding dividends, fees and charges).

Current consensus price target is $2.10, suggesting upside of 16.2% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates AMP as No Rating (-1) -

AMP has advised the RBNZ has blocked the proposed sale of AMP Life in its current form, and this has the immediate effect that no dividend will be paid out for this half. Macquarie analysts also believe the RBNZ blockage implies a heightened risk that AMP will need to raise capital to strengthen the balance sheet.

Macquarie has placed its rating for AMP Under Review (previously: Neutral). The analysts expect AMP to increase provisions for advice remediation, which, they suggest, could be the catalyst for a fresh raising.

Current Price is $1.81. Target price not assessed.

Current consensus price target is $2.10, suggesting upside of 16.2% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates AMP as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements. Heading into reporting season the broker sees risks tilted to the downside.

AMP target falls to $2.25 from $2.30. Hold retained.

Target price is $2.25 Current Price is $1.81 Difference: $0.44
If AMP meets the Morgans target it will return approximately 24% (excluding dividends, fees and charges).

Current consensus price target is $2.10, suggesting upside of 16.2% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates APT as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Afterpay Touch target rises to $28.85 from $23.43. Add retained.

Target price is $28.85 Current Price is $23.79 Difference: $5.06
If APT meets the Morgans target it will return approximately 21% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates ASX as Reduce (5) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

ASX target rises to $68.24 from $57.10. Reduce retained.

Target price is $68.24 Current Price is $86.07 Difference: minus $17.83 (current price is over target).
If ASX meets the Morgans target it will return approximately minus 21% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $64.15, suggesting downside of -25.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates CAR as Downgrade to Reduce from Add (5) -

Following a strong share price performance, stockbroker Morgans has decided it's time to downgrade Carsales to Reduce from Add, representing a double-step downgrade in its ratings universe.

Looking towards FY20, Morgans finds the company's growth is most likely to consist of single-digit percentage growth and in this context the current valuation is seen as overly rich.

Morgans retains a positive view on Carsales' long-term prospects, but succumbs to the observation that, short-term, the valuation seems to have moved well-ahead of fundamentals. Price target $12.49 (unchanged). Forecasts have been left untouched.

Target price is $12.49 Current Price is $13.72 Difference: minus $1.23 (current price is over target).
If CAR meets the Morgans target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $14.04, suggesting upside of 2.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates CGF as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Challenger's price target falls to $7.37 from $7.39. Hold retained.

Target price is $7.37 Current Price is $6.73 Difference: $0.64
If CGF meets the Morgans target it will return approximately 10% (excluding dividends, fees and charges).

Current consensus price target is $7.31, suggesting upside of 8.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates CPU as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Computershare target falls to $17.56 from $17.92. Hold retained.

Target price is $17.56 Current Price is $16.41 Difference: $1.15
If CPU meets the Morgans target it will return approximately 7% (excluding dividends, fees and charges).

Current consensus price target is $16.76, suggesting upside of 2.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: -0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates CSL as Buy (1) -

The Trump Administration has withdrawn its proposed rebate rule which was intended to stop the practice of pharmacy benefit manager rebates from January 1, 2020. UBS suggests the most likely reason was the cost of implementation.

UBS continues to expect around 15% of the company's global immunoglobulin sales will be exposed to potential reform of the international pricing index, the only remaining comprehensive drug pricing reform available in the US.

A -18% price reduction is estimated, which would reduce valuation by around -6%. No changes are made to forecasts because of the significant uncertainty. Buy rating and $223 target maintained.

Target price is $223.00 Current Price is $221.36 Difference: $1.64
If CSL meets the UBS target it will return approximately 1% (excluding dividends, fees and charges).

Current consensus price target is $212.40, suggesting downside of -4.0% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.5

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates DTL as Downgrade to Hold from Add (3) -

Data#3 has released revised guidance suggesting FY19 profit will be up 28%, 11% ahead of Morgans' forecast. The broker had flagged upside were there to be no election slowdown, and neither the NSW or federal elections produced a slowdown.

The broker rates the company highly but after a 52% rally over twelve months, downgrades to Hold. Target rises to $2.48 from $2.25.

Target price is $2.48 Current Price is $2.55 Difference: minus $0.07 (current price is over target).
If DTL meets the Morgans target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates GDG as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Generation Development target unchanged at 83c. Add retained.

Target price is $0.83 Current Price is $0.52 Difference: $0.31
If GDG meets the Morgans target it will return approximately 60% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates HLO as Buy (1) -

Ord Minnett has re-examined earnings estimates and, while not expecting numbers wildly in excess of its forecast for FY19, considers it unlikely the company will disappoint.

The FY20 result appears to be about cost reductions and, as a result, the market appears to have discounted the stock. Despite this, Ord Minnett is comfortable in the ability of the company to deliver. Buy rating and $6.14 target maintained.

Target price is $6.14 Current Price is $4.73 Difference: $1.41
If HLO meets the Ord Minnett target it will return approximately 30% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.5

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates IAG as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Insurance Australia Group target rises to $7.61 from $7.13. Hold retained.

Target price is $7.61 Current Price is $8.43 Difference: minus $0.82 (current price is over target).
If IAG meets the Morgans target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $7.86, suggesting downside of -6.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates KSL as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Kina Securities target rises to $1.45 from $1.42. Add retained.

Target price is $1.45 Current Price is $1.37 Difference: $0.08
If KSL meets the Morgans target it will return approximately 6% (excluding dividends, fees and charges).

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

This company reports in PGK. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates LNK as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Link Administration target falls to $6.78 from $6.84. Add retained.

Target price is $6.78 Current Price is $5.03 Difference: $1.75
If LNK meets the Morgans target it will return approximately 35% (excluding dividends, fees and charges).

Current consensus price target is $7.05, suggesting upside of 40.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates LVT as Buy (1) -

The company's June quarter update revealed strong Annualised Recurring Revenue (ARR) numbers but Citi analysts nevertheless make the point the growth reported was below expectations.

The analysts seem to blame larger customers as they require a longer sales cycle, making a larger contribution when finally committing. Irrespective, the analysts remain disappointed, retaining the Buy/High Risk rating. Target 94c.

Target price is $0.94 Current Price is $0.53 Difference: $0.41
If LVT meets the Citi target it will return approximately 77% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates MAI as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Mainstream Group target falls to 73c from 80c. Add retained.

Target price is $0.73 Current Price is $0.49 Difference: $0.24
If MAI meets the Morgans target it will return approximately 49% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates MPL as Neutral (3) -

Neutral rating retained as Citi adjusts EPS forecasts (slightly) upon marking-to-market led by stronger bonds (lower yields) and stronger equities. The analysts cannot help but conclude this stock looks expensive given the industry's challenged outlook.

Short term, expectations of more cost-out initiatives and potential for capital return are likely to keep the positive momentum going, which is why the rating is not pulled below Neutral, explain the analysts. Target price lifted to $3.60 from $3.30.

Target price is $3.60 Current Price is $3.58 Difference: $0.02
If MPL meets the Citi target it will return approximately 1% (excluding dividends, fees and charges).

Current consensus price target is $2.92, suggesting downside of -18.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates MPL as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Medibank Private target rises to $3.23 from $2.74. Hold retained.

Target price is $3.23 Current Price is $3.58 Difference: minus $0.35 (current price is over target).
If MPL meets the Morgans target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $2.92, suggesting downside of -18.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates MX1 as Add (1) -

Micro-X has teamed up with a French aerospace-defence-security company to development airport checkpoint security and counter-terrorism systems. A $10m convertible bond has been issued and additional production capacity has been secured in Adelaide.

This takes Micro-X to a higher risk profile, so the broker has moved to Speculative Buy from Add (which remains as add in FNArena's system). Target falls to 47c from 50c.

Target price is $0.47 Current Price is $0.28 Difference: $0.19
If MX1 meets the Morgans target it will return approximately 68% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates NBL as Add (1) -

Noni B has reiterated FY19 guidance of 21% earnings growth, in line with the broker's expectations. Sales in the second half fell -5.5% after falling -3.1% in the first half as the company worked through excess inventory acquired from Specialty Fashion.

FY20 should see a turnaround, the broker suggests. A solid outcome in challenging conditions has the broker retaining Add. Target falls to $3.48 from $4.04.

Target price is $3.48 Current Price is $2.65 Difference: $0.83
If NBL meets the Morgans target it will return approximately 31% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates NEA as Buy (1) -

Citi had initiated coverage with a maiden Buy/High Risk rating in May and, now the pre-release of FY19 numbers has revealed disappointment, grabs the opportunity to reiterate that call, pointing out growth remains robust and the opportunity in North America remains intact.

The analysts have scaled back their sales forecasts, with EBITDA (operational earnings) lowered for FY20 and FY21. Instead of blaming the company for not meeting their forecast for Annualised Contract Value (ACV) in North America, Citi analysts state they had simply been too bullish.

Nearmap is now projected to spend more on marketing, which is incorporated in fresh forecasts. Target is raised to $4.39 from $4.26.

Target price is $4.39 Current Price is $3.31 Difference: $1.08
If NEA meets the Citi target it will return approximately 33% (excluding dividends, fees and charges).

Current consensus price target is $4.25, suggesting upside of 28.4% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates NEA as Outperform (1) -

FY19 preliminary results were slightly behind Macquarie's estimates, although weakness in the share price suggests this is fully reflected and presents a buying opportunity. Cash flow break-even was delivered in line with guidance.

Deployment of growth capital will underpin penetration of the key US market, in the broker's view. Outperform rating maintained. Target is reduced to $4.16 from $4.22.

Target price is $4.16 Current Price is $3.31 Difference: $0.85
If NEA meets the Macquarie target it will return approximately 26% (excluding dividends, fees and charges).

Current consensus price target is $4.25, suggesting upside of 28.4% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgan Stanley rates NEA as Overweight (1) -

Preliminary indications suggest FY19 results are in line with Morgan Stanley's estimates. Break-even on cash flow, excluding the capital raising, has been achieved. The company will release its results on August 21.

Overweight rating, In-Line industry view and $4.20 target maintained.

Target price is $4.20 Current Price is $3.31 Difference: $0.89
If NEA meets the Morgan Stanley target it will return approximately 27% (excluding dividends, fees and charges).

Current consensus price target is $4.25, suggesting upside of 28.4% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates NHF as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Nib Holdings target rises to $7.15 from $6.18. Hold retained.

Target price is $7.15 Current Price is $7.95 Difference: minus $0.8 (current price is over target).
If NHF meets the Morgans target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $5.87, suggesting downside of -26.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates OSH as Neutral (3) -

UBS believes the main focus for investors in the upcoming quarterly production results will be commentary on the PNG FEED timeline as well as a resource upgrade for Alaska prior to FEED. The broker expects a resource upgrade for the latter of around 240mmbbl.

The broker reduces FY19 estimates for earnings per share by -0.6% to reflect mark-to-market changes in oil prices and FX. Neutral rating maintained. Target is reduced to $7.65 from $8.00.

Target price is $7.65 Current Price is $7.34 Difference: $0.31
If OSH meets the UBS target it will return approximately 4% (excluding dividends, fees and charges).

Current consensus price target is $8.26, suggesting upside of 12.6% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates PPT as Hold (3) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Perpetual target rises to $41.72 from $39.99. Hold retained.

Target price is $41.72 Current Price is $41.86 Difference: minus $0.14 (current price is over target).
If PPT meets the Morgans target it will return approximately minus 0% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $39.85, suggesting downside of -4.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: -0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates QBE as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

QBE Insurance's target falls to $12.48 from $13.51. Add retained.

Target price is $12.48 Current Price is $11.81 Difference: $0.67
If QBE meets the Morgans target it will return approximately 6% (excluding dividends, fees and charges).

Current consensus price target is $12.88, suggesting upside of 9.0% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates RHC as Neutral (3) -

Hospital activity data in May in the UK has been published and UBS estimates NHS e-referrals represent around 79% of the company's total admissions. May volumes decreased -1.9% and the three and six-month rolling growth rates now sit at 0.9% and 3.3% respectively.

With Australia representing around 79% of FY20 earnings (EBIT) forecasts, the outlook for private hospital volumes and pricing remains a key driver of the stock, the broker believes. Of the two the risk around price remains paramount.

Neutral rating and $68.40 target maintained.

Target price is $68.40 Current Price is $72.26 Difference: minus $3.86 (current price is over target).
If RHC meets the UBS target it will return approximately minus 5% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $67.16, suggesting downside of -7.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates STO as Upgrade to Outperform from Neutral (1) -

Macquarie upgrades to Outperform from Neutral following the recent pull back in the shares. Target is raised to $8.20 from $7.60.

Several catalysts are expected to de-risk future large-scale development opportunities over the second half including flow-testing of Dorado-3, MacArthur basin drilling, potential Narrabri approvals and the 2019 investor briefing.

Target price is $8.20 Current Price is $7.09 Difference: $1.11
If STO meets the Macquarie target it will return approximately 16% (excluding dividends, fees and charges).

Current consensus price target is $7.08, suggesting downside of -0.2% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY19:

Forecast for FY20:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates SUN as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Suncorp Group target rises to $14.59 from $14.48. Add retained.

Target price is $14.59 Current Price is $13.24 Difference: $1.35
If SUN meets the Morgans target it will return approximately 10% (excluding dividends, fees and charges).

Current consensus price target is $13.74, suggesting upside of 3.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates Z1P as Add (1) -

The broker has marked its sector valuations to market, accounting for stronger equity prices, lower bond yields and currency movements.

Zip Co target rises to $3.52 from $3.19. Add retained.

Target price is $3.52 Current Price is $3.04 Difference: $0.48
If Z1P meets the Morgans target it will return approximately 16% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY19:

Forecast for FY20:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources